Compare XXII & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XXII | NDRA |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 7.3M |
| IPO Year | N/A | 2017 |
| Metric | XXII | NDRA |
|---|---|---|
| Price | $1.04 | $5.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 190.3K | 84.0K |
| Earning Date | 11-04-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,346,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $136.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $0.78 | $2.90 |
| 52 Week High | $294.98 | $11.96 |
| Indicator | XXII | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 51.99 |
| Support Level | $0.98 | $5.08 |
| Resistance Level | $1.09 | $6.24 |
| Average True Range (ATR) | 0.09 | 0.82 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 83.36 | 64.77 |
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.